Allergy Therapeutics plc (LON:AGY – Get Free Report) shares reached a new 52-week high during trading on Monday . The stock traded as high as GBX 7.50 ($0.09) and last traded at GBX 7.36 ($0.09), with a volume of 1111262 shares traded. The stock had previously closed at GBX 7.48 ($0.09).
Allergy Therapeutics Stock Performance
The company has a market cap of £357.75 million, a PE ratio of -125.00, a PEG ratio of -30.70 and a beta of 1.40. The stock has a 50 day simple moving average of GBX 6.07 and a two-hundred day simple moving average of GBX 5.22. The company has a debt-to-equity ratio of 37.22, a current ratio of 1.40 and a quick ratio of 1.48.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Read More
- Five stocks we like better than Allergy Therapeutics
- 3 Small Caps With Big Return Potential
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- What is a Dividend King?
- How Do Stock Buybacks Affect Shareholders?
- Do ETFs Pay Dividends? What You Need to Know
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
